| Affimed is a holding company. Through its subsidiary, Co. is enagaged as a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Co.'s product candidates are developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that harnesses the body's own immune defenses to fight tumor cells. The more potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Co. focuses its research and development efforts on proprietary programs: AFM13, and AFM11. We show 5 historical shares outstanding datapoints in our coverage of AFMD's shares outstanding history.|
Understanding the changing numbers of AFMD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AFMD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AFMD by allowing them to research AFMD shares outstanding history
as well as any other stock in our coverage universe.